Alphyn is developing first-in-class therapeutics for severe and prevalent skin diseases using its unique multiple bioactive Zabalafin Multi-Target Therapeutic Drug Platform. Zabalafin Hydrogel, the company's lead candidate for atopic dermatitis (AD), is at the forefront of an evolution to treat the bacterial cause and exacerbation of the disease, in addition to directly treating the itch, inflammation, and infection that make AD so difficult to manage. AD is a devastating chronic disease with with an estimated market size of $118 billion globally. Current treatments fall short on efficacy and safety for worry-free, long-term, and continuous use, and address only the immune component of the disease. Alphyn is well positioned with a differentiated product that addresses these shortcomings. After two Phase 2a clinical trials showing superiority to current commercial and investigational therapeutics, Zabalafin Hydrogel will begin global Phase 2b trials this year.